Semaglutide vs Retatrutide
| Attribute | Semaglutide GLP-1 receptor agonist | Retatrutide Triple agonist (GLP-1/GIP/Glucagon) |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Weight loss and blood sugar research | Triple-receptor metabolic research |
| In plain English | Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down. | Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date. |
| How it works | Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling. | GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation. |
| Researchers study | Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation. | Obesity, hepatic steatosis, and metabolic syndrome. |
| Internet discussion | The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions. | Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide. |
Semaglutide
Weight loss and blood sugar research
Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down.
Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling.
Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation.
The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions.
Semaglutide is the reference GLP-1 agonist — well-studied for blood sugar control and significant weight reduction.
Retatrutide
Triple-receptor metabolic research
Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date.
GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation.
Obesity, hepatic steatosis, and metabolic syndrome.
Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide.
Retatrutide is an investigational triple agonist showing the largest weight-loss signals in metabolic research to date.